Ai D, Zhu H, Ren W, Chen Y, Liu Q, Deng J, Ye J, Fan J, Zhao K (2017) Patterns of distant organ metastases in esophageal cancer: a population-based study. J Thorac Dis 9(9):3023–3030. https://doi.org/10.21037/jtd.2017.08.72

Article  PubMed  PubMed Central  Google Scholar 

Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Hsiao CC, Shih LH, Chen SW, Li SH (2018) Neck lymph node metastasis as a poor prognostic factor in thoracic esophageal squamous cell carcinoma patients receiving concurrent chemoradiotherapy: a propensity score-matched analysis. Sci Rep 8(1):15073. https://doi.org/10.1038/s41598-018-33400-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang R, Qiu Z, Zheng C, Zeng R, Chen W, Wang S, Li E, Xu Y (2022) Neoadjuvant therapy for locally advanced esophageal cancers. Front Oncol 12:734581. https://doi.org/10.3389/fonc.2022.734581

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y (2019) Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(11):1506–1517. https://doi.org/10.1016/S1470-2045(19)30626-6

Article  CAS  PubMed  Google Scholar 

Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, Bennouna J, Kato K, Shen L, Enzinger P, Qin SK, Ferreira P, Chen J, Girotto G, de la Fouchardiere C, Senellart H, Al-Rajabi R, Lordick F, Wang R, Suryawanshi S, Bhagia P, Kang SP, Metges JP, Investigators K (2020) Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol 38(35):4138–4148. https://doi.org/10.1200/JCO.20.01888

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547):373–377. https://doi.org/10.1038/nature14292

Article  CAS  PubMed  Google Scholar 

Burr JL, Johnson KC, Carmicheal JJ, Lin C, Ganti AK (2024) Combination immunotherapy with radiotherapy in non-small cell lung cancer: a review of evidence. Cancer Med 13(21):e70402. https://doi.org/10.1002/cam4.70402

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fitzgerald K, Simone CB 2nd (2020) Combining immunotherapy with radiation therapy in non-small cell lung cancer. Thorac Surg Clin 30(2):221–239. https://doi.org/10.1016/j.thorsurg.2020.01.002

Article  PubMed  Google Scholar 

Manukian G, Bar-Ad V, Lu B, Argiris A, Johnson JM (2019) Combining radiation and immune checkpoint blockade in the treatment of head and neck squamous cell carcinoma. Front Oncol 9:122. https://doi.org/10.3389/fonc.2019.00122

Article  PubMed  PubMed Central  Google Scholar 

Mine S, Tanaka K, Kawachi H, Shirakawa Y, Kitagawa Y, Toh Y, Yasuda T, Watanabe M, Kamei T, Oyama T, Seto Y, Murakami K, Arai T, Muto M, Doki Y (2024) Japanese classification of esophageal cancer, 12th edition: part I. Esophagus 21(3):179–215. https://doi.org/10.1007/s10388-024-01054-y

Article  PubMed  PubMed Central  Google Scholar 

Doki Y, Tanaka K, Kawachi H, Shirakawa Y, Kitagawa Y, Toh Y, Yasuda T, Watanabe M, Kamei T, Oyama T, Seto Y, Murakami K, Arai T, Muto M, Mine S (2024) Japanese classification of esophageal cancer, 12th edition: part II. Esophagus 21(3):216–269. https://doi.org/10.1007/s10388-024-01048-w

Article  PubMed  PubMed Central  Google Scholar 

Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, Takiyama W, Ishida K, Isono K, Makuuchi H, Imamura M, Shinoda M, Ikeuchi S, Kabuto T, Yamana H, Fukuda H (2001) Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 31(9):419–423. https://doi.org/10.1093/jjco/hye090

Article  CAS  PubMed  Google Scholar 

Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M (2004) Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 34(10):615–619. https://doi.org/10.1093/jjco/hyh107

Article  PubMed  Google Scholar 

Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I (2016) PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 21(3):462–473. https://doi.org/10.1007/s10147-016-0959-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lecoester B, Wespiser M, Marguier A, Mirjolet C, Boustani J, Adotevi O (2023) Chemotherapy to potentiate the radiation-induced immune response. Int Rev Cell Mol Biol 376:143–173. https://doi.org/10.1016/bs.ircmb.2023.01.004

Article  CAS  PubMed  Google Scholar 

Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, Spigel DR, Garassino MC, Reck M, Senan S, Naidoo J, Rimner A, Wu YL, Gray JE, Ozguroglu M, Lee KH, Cho BC, Kato T, de Wit M, Newton M, Wang L, Thiyagarajah P, Antonia SJ (2021) Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial. J Thorac Oncol 16(5):860–867. https://doi.org/10.1016/j.jtho.2020.12.015

Article  CAS  PubMed  Google Scholar 

Filippi AR, Fava P, Badellino S, Astrua C, Ricardi U, Quaglino P (2016) Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiother Oncol 120(1):1–12. https://doi.org/10.1016/j.radonc.2016.06.003

Article  CAS  PubMed  Google Scholar 

Qian JM, Schoenfeld JD (2020) Radiotherapy and immunotherapy for head and neck cancer: current evidence and challenges. Front Oncol 10:608772. https://doi.org/10.3389/fonc.2020.608772

Article  PubMed  Google Scholar 

Chumsri S, Sokol ES, Soyano-Muller AE, Parrondo RD, Reynolds GA, Nassar A, Thompson EA (2020) Durable complete response with immune checkpoint inhibitor in breast cancer with high tumor mutational burden and APOBEC signature. J Natl Compr Canc Netw 18(5):517–521. https://doi.org/10.6004/jnccn.2020.7543

Article  CAS  PubMed  Google Scholar 

Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, Zaidi N, Azad NS, Laheru DA, Frampton GM, Jaffee EM (2019) PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 4(6). https://doi.org/10.1172/jci.insight.126908

Maleki Vareki S (2018) High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer 6(1):157. https://doi.org/10.1186/s40425-018-0479-7

Article  PubMed  PubMed Central  Google Scholar 

Egiziano G, Bernatsky S, Shah AA (2016) Cancer and autoimmunity: harnessing longitudinal cohorts to probe the link. Best Pract Res Clin Rheumatol 30(1):53–62. https://doi.org/10.1016/j.berh.2016.03.001

Article  PubMed  PubMed Central  Google Scholar 

Pol J, Paillet J, Plantureux C, Kroemer G (2022) Beneficial autoimmunity and maladaptive inflammation shape epidemiological links between cancer and immune-inflammatory diseases. Oncoimmunology 11(1):2029299. https://doi.org/10.1080/2162402X.2022.2029299

Article  PubMed  PubMed Central  Google Scholar 

Sparks JA (2024) Pre-existing autoimmune diseases and immune checkpoint inhibitors for cancer treatment: considerations about initiation, flares, immune-related adverse events, and cancer progression. Rheum Dis Clin North Am 50(2):147–159. https://doi.org/10.1016/j.rdc.2024.01.001

Article  PubMed  Google Scholar 

Hudis CA, Schmitz N (2004) Dose-dense chemotherapy in breast cancer and lymphoma. Semin Oncol 31(3 Suppl 8):19–26. https://doi.org/10.1053/j.seminoncol.2004.04.004

Article  CAS  PubMed  Google Scholar 

Mooney MR, Geerts D, Kort EJ, Bachmann AS (2019) Anti-tumor effect of sulfasalazine in neuroblastoma. Biochem Pharmacol 162:237–249. https://doi.org/10.1016/j.bcp.2019.01.007

Article  CAS  PubMed  Google Scholar 

Muerkoster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Folsch UR, Schafer H (2003) Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 104(4):469–476. https://doi.org/10.1002/ijc.10963

Article  CAS  PubMed  Google Scholar